The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized, open-label, phase 3 study of ZL-1310, a DLL3 antibody-drug conjugate (ADC), compared to investigator’s choice therapy in participants with relapsed small cell lung cancer (DLLEVATE).
 
Afshin Dowlati
Consulting or Advisory Role - Abbvie/Stemcentrx; Amgen; AstraZeneca; Tempus
Research Funding - Abbvie/Stemcentrx (Inst); Amgen (Inst); Astellas Pharma (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); Bristol-Myers Squibb (Inst); Gilead Sciences (Inst); Ipsen (Inst); Lilly/ImClone (Inst); Mirati Therapeutics (Inst); Seagen (Inst); Takeda (Inst)
 
Raffaele Califano
Stock and Other Ownership Interests - LOC @ TCPC; supportive care UK
Honoraria - AstraZeneca; GlaxoSmithKline; Janssen Oncology; MSD; Pfizer; Roche; Takeda
Consulting or Advisory Role - Janssen; PharmaMar
Speakers' Bureau - Janssen; Takeda
Research Funding - ArriVent Biopharma (Inst); AstraZeneca (Inst); GlaxoSmithKline (Inst); MSD (Inst); PharmaMar (Inst); roche (Inst); Taiho Oncology (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Janssen Oncology; Takeda
 
Koichi Goto
Honoraria - Amgen; Amoy Diagnostics; ArriVent Biopharma, Inc.; AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb K.K.; Bristol-Myers Squibb K.K.; Chugai Pharma; DAIICHI SANKYO Co., Ltd.; Eisai; Janssen; Lilly Japan; Merck; Novartis; Ono Pharmaceutical; Sysmex; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific
Consulting or Advisory Role - Amgen; Amplity, Inc.; ArriVent Biopharma, Inc.; Bayer HealthCare Pharmaceuticals Inc.,; Boehringer Ingelheim; Bristol-Myers Squibb K.K.; DAIICHI SANKYO Co., Ltd.; GlaxoSmithKline K.K.; Guardant Health Japan Corp.; Haihe Biopharma Co., Ltd.; iTeos Therapeutics Inc.; Lilly Japan; Nippon Boehringer Ingelheim; Novartis; Pfizer; Pharma Mar, S.A.; Taiho Pharmaceutical
Research Funding - AbbVie Inc., (Inst); AccuraGen Inc. (Inst); Amgen (Inst); AnHeart Therapeutics Inc. (Inst); ArriVent Biopharma, Inc. (Inst); AstraZeneca Japan (Inst); Bayer Yakuhin (Inst); BillionToOne, Inc. (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb K.K. (Inst); Chugai Pharma (Inst); CRAIF Inc. (Inst); DAIICHI SANKYO Co., Ltd. (Inst); Eisai (Inst); Guardant Health Asia, Middle East & Africa, Inc (Inst); HaiHe Biopharma Co., Ltd. (Inst); Ignyta (Inst); Janssen (Inst); Kyowa Kirin Co., Ltd. (Inst); Lilly Japan (Inst); Loxo (Inst); Lunit (Inst); MEDICAL & BIOLOGICAL LABORATORIES CO., LTD. (Inst); Merus (Inst); MSD K.K. (Inst); Nippon Kayaku (Inst); Nippon Kayaku (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); RIKEN GENESIS CO., LTD. (Inst); Spectrum Pharmaceuticals (Inst); Sumitomo Pharma Co., Ltd. (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Turning Point Therapeutics (Inst)
 
Maurice Perol
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Gilead Sciences; GlaxoSmithKline; IPSEN; Janssen Oncology; Lilly; Merck Sharp & Dohme; Novartis; Novocure; Nuvation Bio; Pfizer; Roche/Genentech; Sanofi; Takeda
Research Funding - Takeda (Inst)
Expert Testimony - Amgen; AstraZeneca
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Merck Sharp & Dohme; Pfizer; Roche; Takeda
 
Yi-Long Wu
Honoraria - AstraZeneca; BeiGene Beijing; Boehringer Ingelheim; Bristol-Myers Squibb/China; Hengrui Pharmaceutical; MSD Oncology; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Roche; Takeda
Research Funding - BMS (Inst); Boehringer Ingelheim (Inst); Pfizer (Inst); Roche (Inst)
 
Ralph Boccia
Honoraria - Abbvie/Genentech; AstraZeneca; BeiGene; BMS; DSI; Genmab; Janssen; Sobi
Consulting or Advisory Role - BMS; Janssen
Speakers' Bureau - AstraZeneca; DSI; Janssen
Research Funding - Amgen (Inst); AstraZeneca (Inst); DSI (Inst); Genentech (Inst); Janssen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Janssen
 
Paul Fishkin
Employment - Illinois CancerCare, PC
Leadership - illinois Cancer Care
Stock and Other Ownership Interests - Johnson & Johnson; Novartis; Unilever
 
John Hamm
Consulting or Advisory Role - Amgen; Boehringer Ingelheim; Jazz Pharmaceuticals; Meda Pharmaceuticals; Novocure
Research Funding - Abbvie (Inst); Amgen (Inst); ARMO BioSciences (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Beijing Avistone Biotechnology Co., Ltd. (Inst); BioNTech SE (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); BrightPath Biotheraputics (Inst); Bristol-Myers Squibb (Inst); Cancer Research and Biostatistics (Inst); Celgene (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Dana-Farber Cancer Institute (Inst); Deciphera (Inst); DualityBio (Inst); EMD Serono (Inst); EpicentRx (Inst); Exact Sciences (Inst); F Hoffmann-LaRoche Ltd. (Inst); Five Prime Therapeutics (Inst); G1 Therapeutics (Inst); GBG Forschungs (Inst); Genentech (Inst); Genmab (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Gynecologic Oncology Group (Inst); Halozyme (Inst); Immunicum (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); InhibRx (Inst); Janssen (Inst); Jiangsu Hengrui Medicine (Inst); Johnson & Johnson (Inst); Lantern Pharma (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); Moffitt (Inst); National Surgical Adjuvant Breast and Bowel Project (Inst); Nektar (Inst); NiKang Therapeutics (Inst); Novartis (Inst); OncoC4 (Inst); OncoMed (Inst); Pfizer (Inst); PharmaMar (Inst); Plexxikon (Inst); Pronova (Inst); Regeneron (Inst); Regeneron (Inst); Roche (Inst); Sarah Cannon Research Institute (Inst); Seagen (Inst); Spectrum Pharmaceuticals (Inst); SWOG (Inst); Systimmune (Inst); Zymeworks (Inst)
 
Benjamin Jacobs
No Relationships to Disclose
 
Melissa Johnson
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); BeOne Medicines (Inst); Biohaven Pharmaceuticals (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Ellipses Pharma (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Janssen Oncology (Inst); Jazz Pharmaceuticals (Inst); Lilly (Inst); Merck (Inst); Nuvalent, Inc. (Inst); Ottimo Pharma (Inst); Pfizer (Inst); Regeneron (Inst); Revolution Medicines (Inst); Summit Therapeutics (Inst); Zai Lab (Inst)
Research Funding - Adaptimmune (Inst); Amgen (Inst); ArriVent Biopharma (Inst); AstraZeneca (Inst); Bayer (Inst); Black Diamond Therapeutics (Inst); BlossomHill Therapeutics (Inst); Boehringer Ingelheim (Inst); Boundless Bio (Inst); Bristol-Myers Squibb (Inst); Carisma Therapeutics (Inst); Conjupro Biotherapeutics (Inst); Corvus Pharmaceuticals (Inst); D3 Bio (Inst); Daiichi Sankyo (Inst); Erasca, Inc (Inst); Exelixis (Inst); Genentech/Roche (Inst); Genmab (Inst); Genocea Biosciences (Inst); Harpoon (Inst); Helsinn Healthcare (Inst); IDEAYA Biosciences (Inst); IGM Biosciences (Inst); Immuneering (Inst); Immunitas (Inst); Immunocore (Inst); Incyte (Inst); Janssen (Inst); Lilly (Inst); LockBody Therapeutics (Inst); Loxo (Inst); Merck (Inst); Merus (Inst); Mirati Therapeutics (Inst); Modex Therapeutics (Inst); Mythic Therapeutics (Inst); NeoImmuneTech (Inst); Neovia Oncology (Inst); Nextpoint (Inst); Novartis (Inst); Nuvalent, Inc. (Inst); OncoC4 (Inst); Palleon Pharmaceuticals (Inst); Pfizer (Inst); Pierre Fabre (Inst); PMV Pharma (Inst); Prelude Therapeutics (Inst); Puma Biotechnology (Inst); RasCal (Inst); Regeneron (Inst); Revolution Medicines (Inst); Ribon Therapeutics (Inst); Shanghai Junshi BioSciences (Inst); Shattuck Labs (Inst); Silicon Therapeutics (Inst); Summit Therapeutics (Inst); Systimmune (Inst); Taiho Oncology (Inst); TCR2 Therapeutics (Inst); Tempest Therapeutics (Inst); TheRas (Inst); Tizona Therapeutics, Inc. (Inst); Vividion Therapeutics (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; Genentech; Incyte; Merck; Pfizer; Sanofi
 
Gopal Kunta
No Relationships to Disclose
 
Santosh Nair
No Relationships to Disclose
 
Manish Patel
Leadership - ION Pharma
Consulting or Advisory Role - Accutar Biotech; Daiichi Sankyo/UCB Japan; Johnson & Johnson/Janssen; Kura Oncology; Mitsubishi Tanabe Pharma; shivanka Research
Research Funding - Abbvie (Inst); Abdera Thereapeutics (Inst); Accutar Biotech (Inst); Adagene (Inst); Agenus (Inst); Allorion Therapeutics (Inst); Apollo (Inst); Artios (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Avenzo (Inst); BioNTech SE (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb/Celgene (Inst); Compugen (Inst); Conjupro Biotherapeutics (Inst); Cullinan Oncology (Inst); cyteir (Inst); D3 Bio (Inst); Daiichi Sankyo (Inst); Genentech/Roche (Inst); Georgiamune (Inst); Hotspot Therapeutics (Inst); Immune-Onc Therapeutics (Inst); Immunitas (Inst); Immunogen (Inst); Incyte (Inst); Janssen (Inst); Kineta (Inst); Kura Oncology (Inst); Lilly (Inst); Loxo (Inst); Macrogenics (Inst); Medlink (Inst); Merck (Inst); Moderna Therapeutics (Inst); Novartis (Inst); nurix (Inst); Olema Oncology (Inst); OnCusp Therapeutics (Inst); Pfizer (Inst); Prelude Therapeutics (Inst); Ribon Therapeutics (Inst); Seven and Eight Biopharmaceuticals (Inst); Step Pharma (Inst); Sutro Biopharma (Inst); Syndax (Inst); Systimmune (Inst); TeneoBio (Inst); Vividion Therapeutics (Inst); Zai Lab (Inst); Zymeworks (Inst)
 
Caleb Smith
Travel, Accommodations, Expenses - A2 Biotherapeutics
 
Yifan Tu
No Relationships to Disclose
 
Jun Zhang
Consulting or Advisory Role - AstraZeneca; Fosun Pharma; Novocure; Regeneron; Sanofi; Takeda
Speakers' Bureau - AstraZeneca; MJH Life Sciences; Regeneron; Sanofi
Research Funding - Abbvie (Inst); AstraZeneca; BeiGene (Inst); Bridgebio (Inst); Champions Oncology; Genentech/Roche; Hengrui Therapeutics (Inst); Innocare (Inst); Janssen (Inst); KAHR Medical (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics; Mirati Therapeutics (Inst); Nilogen Oncosystems; Novartis (Inst); Takeda
 
Pingkuan Zhang
Employment - Zai Lab
Stock and Other Ownership Interests - Zai Lab
 
Renke Zhou
Employment - Zai Lab
Stock and Other Ownership Interests - Zai Lab
 
Luis Paz-Ares
Leadership - ALTUM Sequencing; Stab Therapeutics
Stock and Other Ownership Interests - Altum Sequencing; Stab therapeutics
Honoraria - Abbvie; Amgen; AstraZeneca; Bayer; BeOne Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Gilead Sciences; GlaxoSmithKline; Janssen; Lilly; Medscape; Merck Serono; MSD; Novartis; Pfizer; PharmaMar; Regeneron; Roche/Genentech; Sanofi; Takeda
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; GlaxoSmithKline; Janssen; Lilly; Merck; Mirati Therapeutics; MSD; Novartis; Pfizer; Pharmamar; Regeneron; Roche; Sanofi; Takeda
Speakers' Bureau - Amgen; AstraZeneca; BeiGene; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; Lilly; Merck Serono; MSD Oncology; Pfizer; Roche/Genentech
Research Funding - AstraZeneca (Inst); MSD (Inst); Pfizer (Inst); PharmaMar (Inst)
Other Relationship - Amgen (I); Astellas Pharma (I); Crinetics Pharmaceuticals (I); Esteve (I); HUTCHMED (I); Ipsen (I); ITM Isotope Technologies Munich (I); Merck (I); Novartis (I); Pfizer (I); Roche (I); Roche (I); Sanofi (I); SERVIER (I)